Homotaurine
| Homotaurine[1] | |
|---|---|
 |
|
|
3-Aminopropane-1-sulfonic acid |
|
|
Other names
Tramiprosat; Alzhemed; 3aps |
|
| Identifiers | |
| CAS number | 3687-18-1 |
| PubChem | 1646 |
| ChemSpider | 1584  |
| KEGG | D06202 |
| ChEMBL | CHEMBL149082 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C3H9NO3S |
| Molar mass | 139.17 g mol−1 |
| Melting point |
293 °C (decomposition) |
| Hazards | |
| R-phrases | R36/37/38 |
| S-phrases | S26 S36 |
 (verify) (what is:  / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Homotaurine (also spelled homotaurin) is a synthetic organic compound. It is analogous to taurine, but with an extra carbon in its chain. Because of its similarity in structure to the neurotransmitter gamma-aminobutyric acid (GABA), it has GABAergic effects and may be useful as an anticonvulsant.[2]
Homotaurine has also been investigated as a potential treatment for Alzheimer's disease. It binds to soluble amyloid beta and inhibits the formation of neurotoxic aggregates that lead to amyloid plaque deposition in the brain.[3] However, clinical trials failed to show value.[4][5]
Homotaurine is a zwitterion at neutral pH.
[edit] References
- ^ Homotaurine at Sigma-Aldrich
- ^ Fariello RG, Golden GT, Pisa M (1982). "Homotaurine (3 aminopropanesulfonic acid; 3APS) protects from the convulsant and cytotoxic effect of systemically administered kainic acid". Neurology 32 (3): 241–5. PMID 7199633.
- ^ Aisen PS, Gauthier S, Vellas B, et al. (2007). "Alzhemed: a potential treatment for Alzheimer's disease". Curr Alzheimer Res 4 (4): 473–8. doi:10.2174/156720507781788882. PMID 17908052.
- ^ "Drugs In Clinical Trials : Alzhemed". Alzheimer Research Forum. http://www.alzforum.org/drg/drc/detail.asp?id=84. Retrieved 1 October 2011.
- ^ "Analysts Skeptical Of Neurochem's Efforts To Salvage Value From Alzhemed". Canada National Post. November 13, 2007. http://www.canada.com/nationalpost/financialpost/investing/story.html?id=1182469f-afb5-41f6-87d6-a2219c489800. Retrieved 1 October 2011.
